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Conclusion:
There are technical and anatomic factors, especially extreme angulation of the carotid artery, that impact the risk of carotid artery angioplasty and stenting.
Summary: It seems clear, at this point, that large randomized clinical trials of 30-day stroke and death rates favor carotid endarterectomy (CEA) over carotid artery stenting (CAS). However, once the perioperative period has passed, CAS and CEA both appear effective in preventing midterm stroke. The implication is decreasing periprocedural rates of CAS would make the procedure more attractive because long-term stroke prevention after CAS or CEA is more equivalent. The authors sought to assess relationships between anatomic and technical factors and 30-day risk of stroke and death after CAS. The authors included patients from the EVA-3S study where carotid stenting was attempted. Two radiologist blinded to clinical data independently assessed the aortic arch and the carotid arteries on procedural angiograms. The authors then also performed a systematic review of studies of CAS that reported 30-day stroke or death risk in relation to arterial anatomy and technique. End points were stroke or death and stroke occurring Յ30 days of CAS. In the EVA-3S trial, 262 patients fulfilled the inclusion criteria, including 13 patients in whom stent insertion failed. The 30-day risk of stroke or death in these patients was 9.5% (n ϭ 25). The risk of stroke or death was higher in patients with internal carotid arterycommon carotid artery angulation Ն60% (RR, 4.96; 2.29-10.74). Risk was lower in patients treated with cerebral protection devices (RR, 0.38; 0.17-0.85).
The authors included 56 studies and 34,398 patients in a systemic review. Risk of stroke or death was higher in patients undergoing left carotid CAS (RR, 1.29; 1.05-1.58, P ϭ .02). Risk of stroke or death was also higher in patients with increased internal carotid artery-common carotid artery angulation (RR, 3.41; 1.52-7.63, P Ͻ .001) and when the target ICA carotid stenosis was Ͼ10 mm in length (RR, 2.36; 1.28-3.38, P ϭ .01). There were nonsignificant trends toward increased risk with CAS in patients with type III aortic arch (RR, 1.82; 0.97-3.41, P ϭ .06), in patients with highly calcified lesions (RR, 1.62; 0.99-2.64, P ϭ .05), and in patients with an ostial location of the ICA stenosis (RR, 1.75; 0.99-3.11, P ϭ .06). Also, in the systematic review, cerebral protection devices were associated with a lower risk of stroke or death (RR, 0.55; 0.41-0.73, P ϭ .02). For the end point of stroke alone, lesion length Ͼ10 mm, aortic arch calcification, ostial location of the stenosis, and stenosis Ͼ90% all were associated with increased risk of CAS (all P Ͻ .05).
Comment: Patient selection is important in reducing the risk of any procedure. This report by the EVA-3S investigators is therefore an important contribution to the CAS literature. Unfortunately, many of the anatomic risk factors for CAS identified will only be discovered during the course of the angiogram accompanying the procedure. Perhaps the incidence of 30-day stroke or death associated with CAS could be decreased if operators were willing to back out of the procedure when an anatomic risk factor for an adverse outcome is identified during the preliminary angio- 
The selective angiotensin I receptor blocker losartan prevents aneurysm progression in a mouse model of Marfan disease with full protection requiring angiotensin II signaling.
Summary: The most common mutation in people with Marfan syndrome involves a cysteine substitution in the epidermal growth factor-like domain of fibrillin-1. In fibrillin-1-deficient mice, the effects of the fibrillin-1 mutation are attenuated by administration of polyclonal transforming growth factor (TGF)-␤-neutralizing antibodies. Protection can also be obtained by treating fribillin-1 mutated mice with losartan, an angiotensin II type I receptor blocker. The authors demonstrate in this work that loss of angiotensin II expression accelerates the aneurysm process in the mouse model of Marfan syndrome. They found full protection of aneurysm degeneration in the mouse model of Marfan syndrome required intact angiotensin II receptor signaling. Enalapril, an angiotensin-converting enzyme inhibitor, limits angiotensin signaling for both angiotensin I and angiotensin II receptors and was less effective in decreasing the aneurysmal degeneration of the aorta in fibrillin-1 mutated mice. The authors demonstrated that although enalapril and losartan both attenuated TGF-␤ signaling in the aorta, only losartan inhibited TGF-␤-mediated activation of ERK, extracellular signal regulated kinase. The data indicate that the protective nature of angiotensin II signaling is necessary for angiotensin-converting enzyme inhibitors to potentially decrease the aneurysmal degeneration of the aorta in mice with fibrillin-1 deficiency resulting from a cysteine substitution. The data indicate losartan reduces ERK1/2 phosphorylation through a combination of inhibiting AT1 receptor-mediated ERK activation and shunting of angiotensin II signaling through the AT2 receptor.
Comment: Remarkable effects of losartan in decreasing aneurysmal degeneration in a mouse model of Marfan syndrome have been previously demonstrated. This study further extends previous work and indicates in the presence of AT1 receptor blocking, ongoing AT2 receptor signaling is required for attenuation of ERK phosphorylation. This appears to be required for the favorable effect of losartan in attenuating aneurysmal degeneration in an animal model of human Marfan disease. Modification of the ERK 1/2 signaling cascade is potentially a therapeutic target for slowing or preventing aneurysmal degeneration in patients with Marfan syndrome.
